Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Varsetatug Masetecan · CX-2051

Antibody-drug conjugate · Cytotoxic, directed at EpCAM (CD326) (EPCAM) · developed by CytomX Therapeutics

Phase 1/2 Most advanced trial
CTMX Developer
2 Registered trials

What is Varsetatug Masetecan?

Varsetatug masetecan (CX-2051) is an antibody-drug conjugate whose anti-EpCAM antibody is masked by a peptide that is cleaved by tumor-associated proteases, so the antibody binds EpCAM-expressing tumor cells. After internalization, a camptothecin derivative is released that inhibits DNA topoisomerase I. It is being studied in solid tumors and colorectal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CX-2051
Drug type
Antibody-drug conjugate
Targets
EpCAM (CD326) (EPCAM), DNA topoisomerase I (TOP1) (secondary target)
Mechanism
Cytotoxic, directed at EpCAM (CD326) (EPCAM)
Pathways
DNA replication inhibition, cell cycle arrest, apoptosis, tumor cell proliferation, migration and invasiveness
Therapy area
Oncology
Developer
CytomX Therapeutics (CTMX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
N2QWC7LB6W

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07900165 Phase 1/2 Colo-rectal Cancer Not yet recruiting CTMX
NCT06265688 Phase 1 Solid Tumor, Adult Recruiting CTMX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colo-rectal CancerSolid Tumor, Adult

Other drugs acting on EPCAM

More from CytomX Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CTMX page.

Follow CTMX, the company behind Varsetatug Masetecan

See CTMX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CTMX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.